SkylineDx Data Confirms Accuracy of the Merlin Test for Low- and High-Risk Melanoma
Source: Dermatology Times, October 2024
Results from Society for Melanoma Research Congress demonstrated excellent predictive power of noninvasive CP-GEP Merlin test.
SkylineDx, an oncology biotechnology company, announced new data from the MERLIN__001 trial, confirming the validity and efficacy of the Merlin test in identifying sentinel lymph node biopsy (SLNB) status in patients with melanoma.
The prospective US multi-center trial is the largest ever conducted to assess the performance of a genomic test for melanoma. The first results from the study were presented at the 2024 Society for Melanoma Research Congress from October 10 to 13 in New Orleans, Louisiana.